Design of Heme Protein-Based Blood Substitutes
基于血红素蛋白的血液替代品的设计
基本信息
- 批准号:7844991
- 负责人:
- 金额:$ 32.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1991
- 资助国家:美国
- 起止时间:1991-08-01 至 2012-05-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAffinityAmino AcidsAnimal ModelAnimalsApoproteinsBacteriaBasic ScienceBindingBiochemicalBiological ModelsBioreactorsBloodBlood BanksBlood PressureBlood SubstitutesBlood capillariesChromosomesChronicCollaborationsComplement component C1sCustomDependenceDeveloping CountriesDevelopmentDisastersDissociationDistalDrug FormulationsEmergency treatmentEngineeringErythroidEscherichia coliFigs - dietaryGenerationsGenesGlobinGoalsHemeHemeproteinsHemoglobinHemorrhageHumanIn VitroInvestmentsLifeManufactured MaterialsMeasuresMilitary PersonnelModelingModificationMolecular ChaperonesMutagenesisMutationMyoglobinOperonOxidative StressOxygenParentsPennsylvaniaPharmacologic SubstancePlesiomonas shigelloidesProblem SolvingProductionPropertyProtein DenaturationProtein EngineeringProteinsProtocols documentationPublic HealthRattusReactionRecombinantsRelative (related person)Research PersonnelResistanceRiceSeriesShigella dysenteriaeSourceSystemTechnologyTexasTherapeuticTransfusionUniversitiesWhole BloodWisconsinapohemoglobinbasecapillarycellular engineeringcommercializationcomparativecostcrosslinkdesignextracellularimprovedin vivomutantoxidationpathogenpre-clinicalpreventprogramsprototypepublic health prioritiesresearch clinical testinguptakevector
项目摘要
DESCRIPTION (provided by applicant): Our long-range goal is to develop recombinant human hemoglobin (rHb) as the starting material for manufacturing all globin-based O2 delivery Pharmaceuticals. We have established the key requirements for a rHb-based blood substitute: (a) moderate O2 affinity and large O2 dissociation rate constants for efficient transport in capillaries; (b) significantly reduced rates of NO scavenging to prevent hypertensive side effects; (c) resistance to auto- and chemically-induced oxidation to inhibit oxidative stress; and (d) low rates of heme dissociation to increase shelf-life. We have used the mechanisms governing these properties to design second-generation extracellular rHb-based blood substitutes with more efficient O2 transport and little or no hypertensive side effect in pre-clinical animal studies. However, there is a clear need to engineer third-generation, non-vasoactive rHbs with increased resistance to denaturation, enhanced expression yields, and reduced production costs. We propose to solve these problems by: (1) optimizing O2 binding to and NO scavenging by human rHb without compromising globin stability and resistance to degradative reactions; (2) improving the stability and enhancing production of recombinant hemoglobin in E. coli by (a) rational and comparative mutagenesis to increase the resistance of the apoprotein to unfolding and (b) co- expression of the alpha and beta rHb chains with the newly discovered erythroid chaperone, alpha hemoglobin stabilizing protein (AHSP); and (3) facilitating rapid incorporation of exogenously added heme into newly synthesized globins by co-expression of rHb with the heme utilization genes (hug) from Plesiomonas shigelloides and related pathogens. PUBLIC HEALTH: We are developing recombinant human hemoglobin to replace donated blood as the source material for all protein-based oxygen carriers that are being developed for the treatment of severe blood loss and believe that this effort should be a national public health priority. An effective hemoglobin- based blood substitute will alleviate chronic shortages of whole blood, provide emergency treatment following military and civilian disasters, and allow the use of transfusions in developing countries lacking a safe blood banking system.
描述(由申请人提供):我们的长期目标是开发重组人血红蛋白(rHb)作为生产所有基于球蛋白的O2输送药物的起始材料。我们已经确定了基于rHb的血液替代品的关键要求:(a)中等的O2亲和力和大的O2解离速率常数,以在毛细血管中有效转运;(B)显著降低NO清除速率,以防止高血压副作用;(c)对自身和化学诱导的氧化的抗性,以抑制氧化应激;和(d)低的血红素解离速率,以增加保质期。我们已经使用这些属性的机制来设计第二代细胞外rHb为基础的血液替代品,更有效的O2运输和很少或没有高血压的副作用,在临床前动物研究。然而,显然需要工程化第三代非血管活性rHb,其具有增加的变性抗性、增强的表达产率和降低的生产成本。我们提出了解决这些问题的方法:(1)优化人rHb与O2的结合和NO的清除,同时不影响球蛋白的稳定性和对降解反应的抗性;(2)提高重组血红蛋白在E.通过(a)合理的和比较性的诱变以增加脱辅基蛋白对解折叠的抗性和(B)α和β rHb链与新发现的红细胞伴侣α血红蛋白稳定蛋白(AHSP)的共表达,在大肠杆菌中表达;和(3)通过rHb与血红素利用基因(hug)的共表达,促进外源血红素快速掺入新合成的球蛋白中来自类志贺邻单胞菌和相关病原体。公共卫生:我们正在开发重组人血红蛋白,以取代捐献的血液,作为所有正在开发用于治疗严重失血的蛋白质氧载体的源材料,并认为这一努力应成为国家公共卫生的优先事项。一种有效的基于血红蛋白的血液替代品将缓解全血的长期短缺,在军事和民用灾难后提供紧急治疗,并允许在缺乏安全血库系统的发展中国家使用输血。
项目成果
期刊论文数量(69)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mechanism of Human Apohemoglobin Unfolding.
人类脱辅血红蛋白的展开机制。
- DOI:10.1021/acs.biochem.6b01235
- 发表时间:2017
- 期刊:
- 影响因子:2.9
- 作者:Samuel,PremilaP;Ou,WilliamC;PhillipsJr,GeorgeN;Olson,JohnS
- 通讯作者:Olson,JohnS
Biophysical and kinetic characterization of HemAT, an aerotaxis receptor from Bacillus subtilis.
- DOI:10.1529/biophysj.104.047936
- 发表时间:2005-04
- 期刊:
- 影响因子:3.4
- 作者:Wei Zhang;J. Olson;G. Phillips
- 通讯作者:Wei Zhang;J. Olson;G. Phillips
Correction: Energetics underlying hemin extraction from human hemoglobin by Staphylococcus aureus.
更正:金黄色葡萄球菌从人血红蛋白中提取血红素的能量学基础。
- DOI:10.1074/jbc.aac120.015267
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Sjodt,Megan;Macdonald,Ramsay;Marshall,JoannaD;Clayton,Joseph;Olson,JohnS;Phillips,Martin;Gell,DavidA;Wereszczynski,Jeff;Clubb,RobertT
- 通讯作者:Clubb,RobertT
Familial secondary erythrocytosis due to increased oxygen affinity is caused by destabilization of the T state of hemoglobin Brigham (ýýýýýýýýýý(Pro100Leu)).
由于氧亲和力增加而导致的家族性继发性红细胞增多症是由血红蛋白 Brigham (Pro100Leu) 的 T 状态不稳定引起的。
- DOI:10.1002/pro.2130
- 发表时间:2012
- 期刊:
- 影响因子:0
- 作者:Mollan,ToddL;Abraham,Bindu;Strader,MichaelBrad;Jia,Yiping;Lozier,JayN;Olson,JohnS;Alayash,AbduI
- 通讯作者:Alayash,AbduI
Passively released heme from hemoglobin and myoglobin is a potential source of nutrient iron for Bordetella bronchiseptica.
血红蛋白和肌红蛋白被动释放的血红素是支气管败血博德特氏菌的营养铁的潜在来源。
- DOI:10.1128/iai.00407-07
- 发表时间:2007
- 期刊:
- 影响因子:3.1
- 作者:Mocny,JeffreyC;Olson,JohnS;Connell,TerryD
- 通讯作者:Connell,TerryD
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN S. OLSON其他文献
JOHN S. OLSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN S. OLSON', 18)}}的其他基金
DESIGN OF HEME-PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
2223331 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
DESIGN OF HEME-PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
3366209 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
Design of Heme Protein Based Blood Substitutes
基于血红素蛋白的血液替代品的设计
- 批准号:
6537007 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
DESIGN OF HEME-PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
3366210 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
DESIGN OF HEME PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
2392678 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
DESIGN OF HEME-PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
3366211 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
DESIGN OF HEME PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
2901154 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
Design of Heme Protein-Based Blood Substitutes
基于血红素蛋白的血液替代品的设计
- 批准号:
7489686 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
DESIGN OF HEME PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
2223333 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
DESIGN OF HEME PROTEIN BASED BLOOD SUBSTITUTES
基于血红素蛋白的血液替代品的设计
- 批准号:
2685381 - 财政年份:1991
- 资助金额:
$ 32.56万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 32.56万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 32.56万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 32.56万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 32.56万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 32.56万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 32.56万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 32.56万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 32.56万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 32.56万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 32.56万 - 项目类别:
Continuing Grant














{{item.name}}会员




